Page last updated: 2024-12-06

uroporphyrin i

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Uroporphyrin I is a porphyrin compound that is a colorless to red-brown crystalline solid. It is an abnormal isomer of protoporphyrin, with all four carboxyl groups in the propionic acid side chains in the same orientation. Uroporphyrin I is synthesized in the biosynthesis pathway of heme, which is a key component of hemoglobin. It is not normally found in humans, but can accumulate in the body in some genetic disorders, such as congenital erythropoietic porphyria. This accumulation can lead to various health problems, including skin photosensitivity, anemia, and neurological issues. Uroporphyrin I is studied to understand the mechanisms of porphyria disorders, and to develop potential therapies for these conditions. It is also used as a marker for the diagnosis of porphyria. In research, it is used to investigate the role of heme biosynthesis in various cellular processes.'

uroporphyrin I: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72424
CHEMBL ID429013
CHEBI ID27484
SCHEMBL ID4327021
MeSH IDM0105311

Synonyms (25)

Synonym
3,8,13,18-tetrakis(carboxymethyl)-21h,23h-porphine-2,7,12,17-tetrapropanoic acid
3-[(5z,10z,14z,19z)-7,12,17-tris(2-carboxyethyl)-3,8,13,18-tetrakis(carboxymethyl)-21,23-dihydroporphyrin-2-yl]propanoic acid
2,7,12,17-porphinetetrapropionic acid
3,8,13,18-tetrakis(carboxymethyl)porphyrin-2,7,12,17-tetrapropionic acid
3,8,13,18-tetrakis(carboxymethyl)porphyrin-2,7,12,17-tetrapropanoic acid
CHEBI:27484
C05767
607-14-7
uroporphyrin i
CHEMBL429013
SCHEMBL4327021
21h,23h-porphine-2,7,12,17-tetrapropanoic acid, 3,8,13,18-tetrakis(carboxymethyl)-
7gca4yue1k ,
unii-7gca4yue1k
3,3',3'',3'''-(3,8,13,18-tetrakis-carboxymethyl-21h,23h-porphine-2,7,12,17-tetrayl)-tetrakis-propionate
3,3',3'',3'''-(3,8,13,18-tetrakis-carboxymethyl-porphyrin-2,7,12,17-tetrayl)-tetra-propionic acid
2,7,12,17-porphinetetrapropionate
3-[7,12,17-tris-(2-carboxy-ethyl)-3,8,13,18-tetrakis-carboxymethyl-22,24-dihydro-porphin-2-yl]-propionate
3,3',3'',3'''-(3,8,13,18-tetrakis-carboxymethyl-porphyrin-2,7,12,17-tetrayl)-tetra-propionate
3-[7,12,17-tris-(2-carboxy-ethyl)-3,8,13,18-tetrakis-carboxymethyl-22,24-dihydro-porphin-2-yl]-propionic acid
3,3',3'',3'''-(3,8,13,18-tetrakis-carboxymethyl-21h,23h-porphine-2,7,12,17-tetrayl)-tetrakis-propionic acid
3,8,13,18-tetrakis(carboxymethyl)porphyrin-2,7,12,17-tetrapropanoate
DTXSID90896979
3,3',3'',3'''-[3,8,13,18-tetrakis(carboxymethyl)porphyrin-2,7,12,17-tetrayl]tetrapropanoic acid
DTXSID80862284

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
Biochemical pathways: part I0466

Bioassays (2)

Assay IDTitleYearJournalArticle
AID106898Inhibition of HIV-1 P24 production.1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1.
AID104239Inhibition of HIV-1 P24 production.1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (44.64)18.7374
1990's15 (26.79)18.2507
2000's12 (21.43)29.6817
2010's2 (3.57)24.3611
2020's2 (3.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.05 (24.57)
Research Supply Index4.06 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index28.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies4 (7.02%)4.05%
Observational0 (0.00%)0.25%
Other53 (92.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]